Analysts expect Akebia Therapeutics to report a Q3 2026 loss of $0.04 per share on revenue of $46.94 million, as the stock trades at approximately $0.71, well below the $3.90 average analyst price target.
Investors are primarily focused on the commercial trajectory of Vafseo, the company's oral treatment for dialysis-related anemia, which is expected to drive long-term growth despite current revenue pressure.
While Vafseo sales grew 60% year-over-year in the previous quarter, overall revenue remains challenged by a significant decline in Auryxia sales due to generic competition and reimbursement shifts.
Market participants are also looking for updates on the VOCAL clinical trial and Vafseo's upcoming transition into the CMS dialysis bundle scheduled for early 2027.